Eversept Partners’s Grace Therapeutics GRCE Stock Holding History

Eversept Partners’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.5M	Buy	+756,600	New	+$2.97M	0.18%	69

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Eversept Partners's GRCE Position: Q1 2026 in Review

Eversept Partners opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 756,600 shares worth $3.5M. The stake represents 0.18% of the portfolio and ranks #69 among its holdings.

34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

Eversept Partners held 756,600 shares of Grace Therapeutics worth $3.5M as of Q1 2026.
Grace Therapeutics was a new Eversept Partners position in Q1 2026.
Grace Therapeutics made up 0.18% of Eversept Partners's portfolio in Q1 2026, its #69 holding.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.